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RNA as a drug target 
Neil D Pearson’ and Catherine D Prescott2 
Historically, the pharmaceutical industry has focused 
on proteins, rather than nucleic acids, as drug targets. 
But recent advances in the fields of RNA synthesis, 
structure determination and therapeutic target 
identification make the systematic exploitation of 
RNA as a drug target a realistic goal. 
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Compared with the structural information available for 
DNA-protein complexes, relatively little is known about 
the structures of RNA-protein complexes. But RNA- 
protein recognition is arguably a variation on the well- 
documented protein-protein recognition paradigms. RNA 
tertiary structure is extremely diverse and provides the 
basis for specific recognition by RNA-binding proteins. In 
contrast, the structure of DNA double helices is essen- 
tially invariable, the major groove is readily accessible and 
DNA-protein recognition is more dependent on sequence 
than tertiary structure. 
Many features of RNA make it attractive as a therapeutic 
target. It is important in many functions of the cell, partic- 
ipating in nearly all macromolecular processes; it is struc- 
turally flexible, both in secondary structure and in tertiary 
structure, suggesting that selective binding should be pos- 
sible; and it lacks a cellular repair mechanism. Drugs tar- 
geted towards ribonucleoprotein (RNP) particles have 
demonstrated therapeutic success in the antibacterial 
area. Here, we will argue that recent advances in the 
fields of RNA synthesis, structure determination and 
therapeutic target identification offer new opportunities 
for drug discovery, especially in the areas of antibacterial 
and antiviral targets. 
Targeting RNA by design: new twists on old themes 
Elucidating the tertiary structure of a therapeutic target 
yields a wealth of information for drug design. But large 
RNAs are notoriously difficult to crystallise and nuclear 
magnetic resonance techniques for structure determina- 
tions are restricted to relatively small fragments of RNA. 
Fortunately, large RNAs are often functional when their 
dissociated parts are non-covalently recombined [ 11. Using 
a reductionist approach, it has therefore been possible to 
make many functionally relevant RNA fragments available 
for structural analysis. 
The detailed structural information available on many 
protein enzymes has successfully aided mechanism-based 
drug design. The ever increasing level of crystallographic 
and biochemical data for ribozymes such as RNase P, 
hammerhead and group I intron [Z], affords another oppor- 
tunity for mechanism-based drug design. For example, 
inhibitors of bacterial RNase P, an essential endoribonu- 
clease that mediates phosphodiester bond cleavage of a 
variety of RNA substrates, are potential drug candidates. 
An understanding of the catalytic properties of RNA has 
led to the development of ‘designer’ ribozymes that site- 
specifically cleave RNA [Z]. The potential for a small mol- 
ecule to fulfil this role is supported by studies on 
bleomycin, which showed that cleavage of RNA occurs in 
a more site-selective manner than for DNA [3]. Improving 
the selectivity for RNA versus DNA may ultimately 
produce site-selective RNA cleaving agents as antibiotics. 
Motif mimicry is another popular approach to drug design. 
Examples in which proteins mimic RNA suggest that 
RNA and proteins have common structural requirements 
for functionality. Familiar strategies for designing small 
molecules that mimic protein motifs may therefore be 
applicable to RNA mimics. For example, the ternary 
complex formed by phenylalanyl tRNA, the non- 
hydrolysable GTP analogue GDPNP, and the translation 
elongation factor Tu (EF-Tu) can be readily superim- 
posed on the complex of elongation factor G (EF-G), the 
tRNA translocase, with GDP (Figure 1; [4]). Both of these 
complexes thus appear to bind to structurally similar sites 
on the ribosome, indicating that common structural ele- 
ments exist between the ribosome’s pre-translocation 
state (when the EF-Tu ternary complex binds) and the 
post-translocation state (when the EF-G-GDP complex is 
released). It has been suggested that domain IV of elonga- 
tion factor G may be a mimic of the anticodon loop of 
tRNA. It may therefore be possible to alter codon-anti- 
codon recognition using drugs designed to mimic a protein 
lead, and this may produce antibacterial agents. 
Exploiting RNA conformational flexibility 
The ability of RNA molecules to exchange between alter- 
native conformations can be essential for biological func- 
tion. But the existence of multiple states may create 
problems for the structure-based design approach men- 
tioned above. Nevertheless, opportunities for therapeutic 
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Figure 1 
(a) 
The structure of the Thermus thermophilus 
elongation factor EF-G. (a) EF-G complexed 
with GDP (EF-G-GDP); (b) the ternary 
complex of Phe-tRNA, Thermus aquaticus 
elongation factor EF-Tu and the non- 
hydrolysable GTP analogue, GDPNP 
(EF-Tu-GDPNP-Phe-tRNAPhe). Domain II in 
EF-G was superimposed on the 
corresponding domain II in EF-TU and the 
structures are shown in a schematic 
representation. The overall shape of the 
structures is similar, suggesting common 
structural requirements for their function on 
the ribosome 141. Figure kindly provided by 
Poul Nisson and reproduced with 
permission [301. 
intervention by restricting conformational exchange should 
not be overlooked. 
It is possible to imagine many ways in which a drug might 
be able to achieve conformational restriction of RNA, 
either by interacting directly with the ligand-binding 
surface or by making use of allosteric effects. Strategies for 
preventing RNA-l&and complex formation include stabil- 
isation of the unbound conformation of RNA, the stabilisa- 
tion of any intermediate state between the free and bound 
conformation of RNA, and the induction and stabilisation 
of unnatural conformations. 
The stabilisation of transient RNA-RNA or RNA-protein 
complexes can also be exploited for drug development. 
For example, the binding of the aminoglycoside antibiotics 
in the major groove of the decoding site of 16s ribosomal 
RNA is proposed to induce an increase in miscoding by 
enhancing the affinity of the codon-anticodon complex for 
the minor groove (Figure 2; [S]). This example also serves 
to illustrate that small molecules that bind in the major or 
minor groove of bulged regions within A-form helical RNA 
can have inhibitory effects either directly or allosterically. 
The possibility that any RNA-drug complex may use 
multiple inhibition mechanisms increases the importance 
of detailed structural information. Recent advances (e.g. 
[5-71) in the synthesis of RNA have already been shown 
to facilitate the structural determination of RNA and 
RNA-drug complexes. 
A new reflection on X-ray crystallography: (D&-RNA 
and (O-RNA 
The unnatural enantiomer of RNA, (L)-RNA (see [8] for 
chemical synthesis), can be combined with the natural 
enantiomer, (D)-RNA, to produce racemic mixtures. 
Because there are 100 additional crystal packing arrange- 
ments available for racemates of optically active molecules 
compared with homochiral- molecules, this combination 
may facilitate crystallisation thereby allowing structural 
studies to be performed. In addition, centrosymmetric 
arrangements of racemates greatly aid structure determi- 
nation using direct methods, simplifying X-ray crystallog- 
raphy by avoiding the need to generate heavy-atom 
derivatives [9]. Furthermore, the exceptional stability of 
(L)-RNA to nucleases may prove valuable in extended 
crystallisation studies. 
Site-specific cross-linking and labelling of RNA 
Many examples of the site-specific attachment of reporter 
and reactive groups using phosphoramidite coupling 
chemistry have been described (e.g. [&lo]). Of particular 
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Figure 2 
The structure of the A-site RNA-paromomycin complex. (a) A best-fit 
superposition of 20 final simulated annealing structures viewed from 
the major groove of the RNA. Only the core of the antibiotic-binding 
site within the RNA (nucleotides U 1406 to Al 410 and U1490 to 
U1495) is shown in purple and paromomycin is yellow. The heavy 
atoms of the core RNA and paromomycin have been superimposed. 
The four rings of paromomycin are numbered. (b) A single 
representative structure of the complex; all heavy atoms are displayed. 
The RNA is shown in purple and paromomycin is tan. The van der 
Waals surface of paromomycin is shown and the four rings are 
numbered as in (a). Figure kindly provided by D. Puglisi and 
reproduced with permission from [5]. Copyright 1996 American 
Association for the Advancement of Science. 
note, are those phosphoramidites that allow post-synthetic 
modification and afford the opportunity to attach a wide 
range of groups using a single phosphoramidite building 
block. In addition, these groups can bear functionality 
incompatible with automated RNA synthesis. For example, 
the selective introduction and modification of Z/-amino 
groups in oligoribonucleotides has been exploited to attach 
disulphides to RNA [LO]. Hence, any molecule containing 
a thiol or thiol-reactive electrophile can be linked to 
the RNA. This could facilitate screen design by allowing 
incorporation of a fluorophore, biotin or another functional 
RNA fragment. 
X-ray crystallography can also be facilitated by the chemical 
synthesis of modified RNA. The presence of non-paired 
bases predisposes RNA to self-aggregation, particularly at 
the concentrations used during crystallisation. Such hetero- 
geneity may prevent successful crystallisation and structure 
determination. The ability to selectively cross-link nucleo- 
tides can make an RNA pseudocyclic, preventing dimerisa- 
tion and facilitating crystallographic studies. For example, 
convertible nucleosides have been used to cross-link an 
eight-nucleotide mini-stem-loop which retained functional 
recognition by the enzyme ricin [ll]. This same method 
could be used to differentiate between alternative folding 
models of RNA fragments. In addition, it can be used to 
stabilise the termini of short RNA helices instead of adding 
extra base pairs, as is more usual. 
Generic insights from single structures 
The X-ray crystal structure of a 160-nucleotide domain of 
the Te&zAymena pre-rRNA group I intron illustrates that a 
wealth of information can be obtained from a single struc- 
ture determination [l&13]. There are many features of this 
structure that can be exploited for target development, 
including the following. 
In the Tetrzzhymena pre-rRNA group I intron, both a 
tetraloop docking into its receptor and intermolecular 
hydrogen bonds between the 2’-hydroxyls of adenosines 
in widened minor grooves may represent motifs that could 
be introduced into non-functional termini of RNA frag- 
ments to increase intermolecular interactions, thereby 
facilitating crystallisation. Furthermore, the structure of 
these motifs defines a function that could in turn define 
therapeutic targets. The ‘adenosine platform’ structural 
motif has a distinctive chemical reactivity [13] which will 
aid its identification in therapeutically important RNA 
targets. This may also provide universal targets for generic 
inhibition strategies. 
Finally, the divalent metal ion binding sites in the major 
groove of helices in the Te~ruhymena group I pre-rRNA 
intron fragment structure are of considerable interest. Diva- 
lent metal ions are directly involved in the catalytic activity 
of ribozymes such as RNase P, and establishing potential 
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binding modes of the catalytically essential metal ions 
could aid the design of antibacterial agents. 
Functional subdomains as therapeutic targets 
RNA performs a variety of functional roles which are medi- 
ated by signals that are a combination of both sequence 
and structure motifs. Detailed analysis of such RNA- 
ligand interactions is hampered by the size and complexity 
of ribonucleoprotein particles and the intrinsic flexibility 
of RNA. The approaches discussed above, of using smaller 
functional analogues or restricting the number of confor- 
mational states by forming RNA-ligand complexes, are 
also applicable to this problem. 
Large RNP complexes can be fragmented into functional 
subdomains that are amenable to detailed investigation 
[14-161. For example, the bacterial 30s ribosomal subunit 
naturally contains three subdomains encompassing the 5’, 
3’ and central domains [17,18]. The 3’ domain can be 
further dissected as exemplified by the generation of an 
oligoribonucleotide analogue encompassing the decoding 
region located near to the 3’ terminus of 16s rRNA [14]. 
This RNA analogue has been shown to interact in vitro 
with both aminoglycoside antibiotics and RNA ligands 
(tRNA and messenger RNA) of the 30s subunit in a 
manner that resembles normal subunit function [5,14]. 
Thus, the presence of a sequence that produces a 
nucleotide bulge results in the formation of an accessible, 
deep and widened major groove that affords a site for 
antibiotic binding. These results offer further evidence 
that therapeutic targets can be discovered by studying 
defined, functionally relevant RNA fragments. 
Cell-based identification of ligand-binding RNA fragments 
A whole-cell approach has also been developed to identify 
RNA fragments that interact with ligands. The ‘RNA frag- 
ment rescue’ concept is based on the premise that express- 
ing an RNA analogue that can bind and thereby sequester 
an antibiotic will ensure the viability of an otherwise 
Figure 3 
sensitive bacterium [ 161. Support for this concept was pro- 
vided by the expression of a 16s rRNA fragment encom- 
passing the spectinomycin-binding domain that conferred 
drug resistance. The potential of this strategy was illus- 
trated further by the selection of additional RNA 
sequence analogues from a mixed pool of RNA fragments 
that conferred spectinomycin resistance [16]. The ana- 
logues shared a common primary sequence and predicted 
structural motifs that have been proposed to form the 
recognition domain for spectinomycin. 
Selection of ligand-binding nucleic acid motifs 
Methods that permit rapid screening, selection and identi- 
fication of the key functional elements involved in inter- 
molecular interactions are clearly advantageous to drug 
research. SELEX (the systematic evolution of ligands by 
exponential enrichment) is arguably the most powerful 
in vitro approach that enables the selection of minimal 
nucleic acid recognition motifs for ligand binding (for 
review see [19]). A wide variety of molecules have been 
targeted including nucleic acid binding proteins [ 19-231, 
non-nucleic acid.binding proteins [24-261 and even antibi- 
otics [27]. For example, SELEX to the HIV-1 Rev protein 
resulted in RNA ligands with striking sequence and sec- 
ondary structural similarities to the high-affinity Rev- 
binding site on the Rev-responsive element (RRE) RNA 
stem IIB [28,29]. Disruption of the rev-RRE interaction 
may afford an antiviral agent. 
Genetic strategies for defining functional protein-RNA 
complexes 
The lack of information detailing how RNA-binding pro- 
teins specifically interact with their target can be attrib- 
uted to the laborious procedures required to generate 
large numbers of proteins with defined amino acid substi- 
tutions, each of which needs to be purified and individu- 
ally characterised. Two genetic strategies (translational 
repression and anti-termination) that permit the rapid 
screening of large numbers of protein and RNA variants 
Amp 
RNA fragment 
The two-plasmid system for measuring 
transcriptional anti-termination by the h N 
protein [31 I. The h N protein binds to the box B 
hairpin of the N utilisation site on the nascent 
RNA transcript. N, along with other host 
factors, forms an anti-termination complex that 
allows RNA polymerase to transcribe through 
termination sites. In the two-plasmid system, h 
N protein is expressed under the control of a 
tat promoter on a pBR322-derived plasmid 
and b-galactosidase, also under control of a 
tat promoter, is expressed on a pACYC- 
derived reporter plasmid, with Nut and 
termination sites upstream of /acZ. Figure 
adapted from [321 with permission. 
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have recently been reported. These strategies can be used 
to identify the key functional elements that modulate 
affinity and specificity of protein-RNA binding. 
Translational repression arises following the formation of a 
stable protein-RNA complex that sterically hinders ribo- 
some binding to a Shine-Dalgarno sequence. This concept 
was adopted to characterise the binding of the HIV Rev 
protein to HIV RRE [30]. Binding of HIV Rev protein to 
RRE inserted immediately upstream of the reporter 
(B-galactosidase) Shine-Dalgarno sequence resulted in 
decreased levels of reporter expression. A series of muta- 
tions introduced into both RRE and Rev were rapidly 
screened and key residues involved in Rev binding, as 
well as suppressor mutations in Rev that rescued the 
binding of altered RRE sequences, were successfully 
identified. The results supported existing evidence that 
the arginine-rich a-helical domain of Rev binds RRE and 
that sequence-specific interactions are mediated through 
amino acids on the non-arginine face of the helix. 
RNA-protein interactions have also been investigated by 
exploiting the interaction between the amino-terminal 
domain of the h N protein and the N utilisation site (Nut) 
RNA stem-loop that precedes the anti-termination site [31]. 
The h N protein-Nut complex signals the recruitment of 
additional factors that form an anti-termination complex 
capable of transcribing through termination signals. The 
system was adapted to identify key residues involved in 
the recognition of RRE by replacing the amino-terminal 
portion of the N protein with an arginine-biased peptide 
library and exchanging the Nut RNA stem-loop with 
RRE (Figure 3; [32]). Specific RNA-peptide interactions 
resulted in expression of the B-galactosidase reporter gene 
located beyond termination sequences. The screen 
resulted in the selection of peptides that matched the Rev 
consensus sequence. 
Both genetic screens provide a powerful means to rapidly 
select and identify critical residues involved in protein- 
RNA interactions and, in so doing, provide complexes 
suitable for the development of high-throughput screens 
for drug-lead identification. 
Conclusions 
The exploitation of RNA as a therapeutic target presents 
three major issues: size, complexity and intrinsic flexibility. 
Drug discovery necessitates the collaboration of synthetic 
chemists, structural chemists and biologists in the defini- 
tion of the precise nature of drug-RNA complexes. Only 
then will the derivation of structure-activity relationships, 
which underpins drug discovery, be reliable. 
References 
1, Westhof, E., Masquida, B. & Jaeger, L. (1996). RNA tectonics: 
towards RNA design. Fold Des. 1, R78R86. 
2. Eckstein, F. & Lilley, D.M.J. (eds) (1996). Cata/yt/c R/VA Volume IO: 
Nucleic Acids and Molecular Biology. Springer-Verlag, Berlin, Germany. 
3. Hecht, S.M. (1994). RNA degradation by bleomycin, a naturally 
occurring bioconjugate. Bioconj. Chem. 5, 513-526. 
4. Nissen, P., et al., & Nyborg, J. (1995). Crystal structure of the ternary 
complex of Phe-tRNAPhe, EF-Tu, and a GTP analog. Science 270, 
1464-1472. 
5. Fourmy, D., Recht, M.I., Blanchard, SC. & Puglisi, J.D. (1996). 
Structure of the A site of fscherichia co/i 16s ribosomal RNA 
complexed with an aminoglycoside antibiotic. Science 274, 
1367-1371. 
6 Scott, W.G., et al., & Klug, A. (1995). Rapid crystallization of 
chemically synthesized hammerhead RNAs using a double screeninq 
procedure. ;. n/ro/. B/o/. 250, 327-332. - 
7 Scott, W.G., Finch, J.T. & Klua. A. (1995). The crystal structure of an 
all-RNA hammerhead ribozyme: a proposed mechanism for RNA 
catalytic cleavage. Cell 81, 99 l-200. 
8. Nolte, A., Klussmann, S., Bald, R., Erdmann, V.A. and Furste, J.P. 
(1996). Mirror-design of L-oligonucleotide ligands binding to 
L-arginine. Nat Biotechnol. 14, 1 1 16-l 1 19. 
9. Toniolo, C., Peggion, C., Crisma, M., Formaggio, F., Shui, X. & 
Eggleston, D.S. (1994). Structure determination of racemic trichogin 
A IV using centrosymmetric crystals. Struct Biol. 1, 908-914. 
10. Sigurdsson, STh. & Eckstein, F. (1996). Site specific labelling of 
sugar residues in oligoribonucleotides: reactions of aliphatic 
isocyanates with 2’ amino groups. Nucleic Acids Res. 24, 3129- 
3133. 
11. Allerson, CR. & Verdine, G.L. (1995). Synthesis and biochemical 
evaluation of RNA containing an intrahelical disulfide crosslink. 
Chem. Biol. 2, 667-675 
12. Cate, J.H., et a/., & Doudna, J.A. (1996). Crystal structure of a group I 
ribozvme domain: principles of RNA packing. Science 273, 1678- 
1686. 
- 
13. Cate, J.H., et al., & Doudna, J.A. (1996). RNA structure mediation by 
adenosine platforms. Science 273, 1696-l 699. 
14. Purohit, P. & Stern, S. (1994). Interactions of a small RNA with 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
antibiotic and RNA ligands of the 30s subunit. Nature 370, 659-662. 
Schroeder, R. (1994). Dissectinn RNA function. Nature 370, 597. 
598. 
Thorn, G. & Prescott, C.D. (1997). The selection and characterization 
of an RNA recognition motif for spectinomycin. Bioorg. Med. Chem., 
in press. 
Yuki, A. & Brimacombe, R. (1975). Nucleotide sequences of 
Escherichia co/i 16-S RNA associated with ribosomal proteins 57, 
S9, SIO, 514 and Si 9. Eur. J. Biochem. 56, 23-34. 
Samaha, R.R., O’Brien, T., O’Brien, B. & Noller, H.F. (1994). 
Independent in vitro assembly of a ribonucleoprotein particle 
containing the 3’ domain of 16s rRNA. Proc. Nat/ Acad. Sci. USA 91, 
7884-7888. 
Gold, L. (1995). Conformational properties of oligonucleotides. 
Nucleic Acids Symp. Ser. 33, 20-22. 
Tuerk, C. & Gold, L. (1990). Systematic evolution of ligands by 
exponential enrichment: RNA ligands to bacteriophage T4 DNA 
polymerase. Science 249, 505510. 
Bartel, D.P., Zapp, M.L., Green, M.R. & Szostak, J.W. (1991). HIV-1 
Rev regulation involves recognition of non-Watson-Crick base pairs in 
viral RNA. Cell 67, 529-536. 
Schneider, D., Tuerk, C. & Gold, L. (1992). Selection of high affinity 
RNA ligands to the bacteriophage R17 coat protein. J. Mol. Biol. 228, 
862-869. 
Tuerk, C., MacDougal, S. & Gold, L. (1992). RNA pseudoknots that 
inhibit human immunodeficiency virus type 1 reverse transcriptase. 
Proc. Nail Acad. Sci. USA 89, 6988-6992. 
Jellinek, D., Lynott, C.K., Rifkin, D.B. &Jan&, N. (1993). High-affinity 
RNA ligands to basic fibroblast growth factor inhibit receptor binding. 
Proc. Nat/ Acad. Sci. USA 90, 11227-l 1231. 
Nieuwlandt, D., Wecker, M. & Gold, L. (1995). In vitro selection of 
RNA ligands to substance P. Biochemistry 34, 5651-5659. 
Binkley, J., Allen, P., Brown, D.M., Green, L., Tuerk, C. & Gold, L. 
(1995). RNA ligands to human nerve growth factor. Nucleic Acids 
Res. 23, 3198-3205. 
Wallis, M.G., Von Ahsen, U., Schroeder, R. & Famulok, M. (1995). A 
novel RNA motif for neomycin recognition. Chem. Biol. 2, 543-552. 
Heaphy, S., Dingwall, C., Ernberg, I., Gait, M. & Skinner, M.A. (1990). 
HIV-1 regulator of virion expression (Rev) protein binds to an RNA 
stem-loop structure located within the Rev response element region. 
Cell 60, 685-693. 
414 Chemistry & Biology 1997, Vol 4 No 6 
29. Heaphy, S., Finch, J.T., Gait, M., Karn, J. & Singh, M. (1991). Human 
immunodeficiency virus type 1 regulator of virion expression, Rev, 
forms nucleoprotein filaments after binding to a purine-rich ‘bubble’ 
located within the Rev-responsive region of viral mRNAs. Proc. /Vat/ 
Acad. SC;. USA 88, 7366-7370. 
30. Jain, C. & Belasco, J.G. (1996). A structural model for the HIV-1 
Rev-RRE complex deduced from altered-specificity Rev variants 
isolated by a rapid genetic strategy. Cell 87, 115-I 25. 
31. Franklin, N.C. (1993). Clustered arginine residues of bacteriophage 
lambda N protein are essential to antitermination of transcription, but 
their locale cannot compensate for boxB loop defects. L ii/lo/. Biol. 
231, 343-360. 
32. Harada, K., Martin, S.S. & Frankel, A.D. (1996). Selection of 
RNA-binding peptides in viva. Nature 380, 175-l 79. 
